Liquidia Technologies is trading 4.31% up at $69.80 on broad strength across biotechnology stocks.
- Biotech is up 2.75% on patent-related enthusiasm and renewed momentum; major U.S. indices are also higher.
- No company-specific announcement was identified for September 2, 2026; the latest major update, an August 12 second-quarter report, showed strong Yutrepia sales but a slight adjusted-EPS miss.
- Trading activity is elevated enough to produce a significant intraday gain, but no specific volume figure is available.